| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EP3 |
| Uniprot No | P43115 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-53aa |
| 氨基酸序列 | MKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSVSVA |
| 预测分子量 | 12.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于EP3重组蛋白的模拟参考文献示例(实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Structural insights into the human EP3 receptor signaling through cryo-EM*
**作者**：Smith, J. et al.
**摘要**：通过冷冻电镜解析了人源EP3受体与Gi蛋白复合物的高分辨率结构，揭示了EP3受体特异性结合前列腺素E2(PGE2)的分子机制及其下游信号传导途径。
2. **文献名称**：*EP3 receptor-mediated activation of Rho signaling in inflammatory response*
**作者**：Tanaka, K. et al.
**摘要**：研究利用重组EP3受体蛋白，证明其在炎症反应中通过激活Rho/ROCK通路调控细胞迁移和血管通透性，为靶向EP3的抗炎药物开发提供依据。
3. **文献名称**：*Functional characterization of recombinant EP3 isoforms in colitis models*
**作者**：Li, X. & Chen, W.
**摘要**：通过表达重组EP3受体不同剪接变体(EP3α/β/γ)，发现EP3γ亚型在结肠炎小鼠模型中特异性加剧肠道炎症反应，提示其作为治疗靶点的潜力。
4. **文献名称**：*Development of EP3-selective antagonists using recombinant receptor screening*
**作者**：Müller, R. et al.
**摘要**：基于重组EP3蛋白的高通量筛选平台，鉴定出新型小分子拮抗剂，可特异性阻断EP3受体介导的cAMP抑制，并在疼痛模型中验证其疗效。
---
**注**：以上为模拟文献示例，实际研究需检索PubMed、Web of Science等数据库获取真实文献(关键词：EP3 receptor, recombinant protein, prostaglandin signaling)。
EP3. a G protein-coupled receptor (GPCR) belonging to the prostaglandin E2 (PGE2) receptor family, plays a critical role in mediating diverse physiological and pathological processes. It is encoded by the PTGER3 gene and exists as multiple splice variants, contributing to its functional versatility. EP3 is widely expressed in tissues, including the nervous, cardiovascular, and immune systems, where it regulates inflammation, pain perception, fever response, and smooth muscle contraction. Its activation by PGE2 triggers downstream signaling via coupling to different G proteins (Gi, Gs, or Gq), depending on isoform-specific structural variations, leading to varied cellular responses such as cAMP modulation, calcium mobilization, or kinase activation.
Recombinant EP3 proteins are engineered to study receptor-ligand interactions, signaling mechanisms, and therapeutic targeting. Produced through heterologous expression systems (e.g., HEK293 or insect cells), these proteins retain native conformational epitopes and functional domains, enabling in vitro assays, structural studies (e.g., cryo-EM), and drug screening. EP3’s involvement in diseases like cancer, chronic inflammation, and cardiovascular disorders has driven interest in developing selective agonists/antagonists. Recombinant variants facilitate high-throughput screening of compounds aimed at modulating EP3 activity, with potential applications in pain management, anti-inflammatory therapies, and oncology.
Recent advances include the use of engineered EP3 constructs to map ligand-binding pockets and allosteric sites, aiding rational drug design. Challenges remain in addressing isoform-specific signaling bias and minimizing off-target effects. As EP3 emerges as a therapeutic target, recombinant protein tools remain pivotal for unraveling its complex biology and translating findings into clinical interventions.
×
